What Is Processa Pharmaceuticals, Inc. (PCSA) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Processa Pharmaceuticals, Inc.'s intrinsic value is estimated at $2.37, presenting a divided outlook at the current price of $2.39. With an average implied return of -0.8% across a split 4–4 (bull–bear) consensus, the model spread of +212.1% underscores analytical uncertainty. Notably, Dynamic NAV sees the most upside at +120.3% (fair value: $5.27), while ML-RIV is the most conservative at -91.8% ($0.20). The spread between these extremes — +212.1% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About PCSA?
8 of 13 models are currently active for PCSA. Of these, 4 models suggest upside while 4 models suggest overvaluation. The Bayesian DCF estimates PCSA's intrinsic value at $0.83, implying -65.3% downside from the current price. See which stocks rank higher →
How Does PCSA Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, PCSA ranks #333 by Quality of Company score. CirclFi's QOC score of 4.0/10 evaluates 32 fundamental signals. A score of 4.0 signals below-average fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Within the Pharmaceutical Preparations space, Processa Pharmaceuticals, Inc. competes in an environment where patent cliff exposure often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is PCSA a Value Trap?
CirclFi's Value Trap algorithm assigns PCSA a score of 39/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
8 of 13 models are active for Processa Pharmaceuticals, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Processa Pharmaceuticals, Inc. is rated at 4.0/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.
The gap between the most bullish and bearish model spans +212.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every PCSA valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across PCSA's 8 active models, average confidence is 27%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad